Following FDA approval in December 2025, the U.S. launch of Novo Nordisk’s Wegovy pill triggered a 17% uptick in shares over the past month, even as the stock remains roughly 15% below its 52-week high near 94. Investors have seized on the company’s first‐mover advantage in the oral GLP-1 weight-loss segment, rewarding management for diversifying beyond injectable formulations. Short‐term technical indicators, including a sustained move above both 20-day and 50-day moving averages, underscore renewed bullish sentiment despite a still bearish 200-day trend.

Clinical trials reveal that patients remaining on Wegovy pill achieved an average weight reduction of 16.6%, versus just 2.7% for placebo, while intention-to-treat analyses showed 13.6% versus 2.4% respectively. The product is offered in four dose levels—1.5 mg, 4 mg, 9 mg and 25 mg—and carries a tiered pricing structure: an introductory rate of $149/month for starter and mid-range doses through mid-April 2026, rising to $199/month thereafter, with top-dose patients paying $299/month. Commercially insured individuals may access the therapy for as little as $25 per month under Novo Nordisk’s savings program.

By adding the oral GLP-1 contender to its obesity and metabolic franchise, Novo Nordisk strengthens its defenses against rival pipelines, particularly those under development by Eli Lilly. Success in translating early uptake into sustained volume could bolster pricing authority across both injection and oral channels. Should the company simultaneously capitalize on tel ehealth partnerships and expand its NovoCare® support network, analysts anticipate a significant rerating catalyst, potentially driving multiples closer to the levels observed during the 52-week peak.